Enovis (NYSE:ENOV) Insider Oliver Engert Acquires 5,140 Shares

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 5,140 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was acquired at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the transaction, the insider owned 61,238 shares of the company’s stock, valued at $1,191,691.48. This represents a 9.16% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Wednesday, September 2nd, Oliver Engert acquired 2,458 shares of Enovis stock. The shares were acquired at an average price of $20.32 per share, with a total value of $49,946.56.
• On Monday, June 15th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average cost of $20.92 per share, for a total transaction of $20,920.00.
• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The stock was acquired at an average price of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were acquired at an average cost of $23.00 per share, with a total value of $23,000.00.

Enovis Stock Down 4.2%

ENOV stock opened at $18.58 on Friday. The firm has a market cap of $1.07 billion, a PE ratio of -0.96 and a beta of 1.31. Enovis Corporation has a 12 month low of $18.52 and a 12 month high of $34.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The firm has a 50 day simple moving average of $25.50 and a 200 day simple moving average of $24.20.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Key Stories Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ENOV shares. UBS Group reaffirmed a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Finally, Wells Fargo & Company reduced their price objective on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $40.38.

Institutional Investors Weigh In On Enovis

A number of hedge funds and other institutional investors have recently made changes to their positions in ENOV. Amundi lifted its holdings in shares of Enovis by 397.7% during the 2nd quarter. Amundi now owns 369,189 shares of the company’s stock valued at $7,642,000 after buying an additional 295,005 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Enovis in the second quarter worth approximately $559,000. California State Teachers Retirement System raised its position in Enovis by 1,635.6% during the second quarter. California State Teachers Retirement System now owns 1,335,833 shares of the company’s stock valued at $27,652,000 after acquiring an additional 1,258,867 shares in the last quarter. Private Management Group Inc. raised its position in Enovis by 38.8% during the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after acquiring an additional 381,705 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in Enovis in the second quarter valued at approximately $48,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.